← Russell 3000 cross-section

TARS Tarsus Pharmaceuticals, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$3.1bn
Revenue TTM
$606m
Net income TTM
$-46m
Free cash flow
$56m
Composite score
60.6
Sector rank
#1371

Valuation

P / E
EV / EBITDA
EV / sales
4.5
FCF yield
1.79%
Earnings yield vs 10-yr
-6.22pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-7.7%
EBITDA margin
-7.6%
ROE
-13.4%
ROIC
Revenue growth
105.2%

Insider activity, last 90 days

Net open-market
$-2.45m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In a Phase 2b/3 RELIEF trial that was completed by iRenix prior to our acquisition of IRX-101, IRX-101 demonstrated statistically significant improvements on two co-primary endpoints versus povidone-iodine: • Pain reduction: Approximately 50% relative reduction in post-procedural pain scores (p=0.0003), with half of the patients in the IRX-101 group reporting a pain score of zero. • Corneal fluorescein staining: Approximately 25% relative reduction in corneal staining in the IRX-101 group (p=0.0003), reflecting less corneal surface damage. …Tarsus Pharmaceuticals, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →